InvestorsHub Logo
icon url

frrol

04/25/17 4:12 PM

#102933 RE: amstocks82 #102929

That is my understanding as well. One of the intriguing possibilities of our theorized MOA's is that we are higher up in the pathways that result in these pathologies, which may yield a broader array of therapeutic effects, like corrective folding of some relevant proteins.

(I add italics to emphasize that so much about our compound remains to be determined. And this is not uncommon in experimental drugs. Heck, even commercialized drugs.)
icon url

falconer66a

04/25/17 5:23 PM

#102941 RE: amstocks82 #102929

The homeostasis (normalized function) restored by Anavex 2-73 is not and should not be regarded as a "side effect." It is the primary, desired outcome --- unlike anything else treating disfunctional neurons.
icon url

OFP

04/25/17 5:31 PM

#102942 RE: amstocks82 #102929

Yes, but it does not do that directly as a chaperone function. Reducing protein misfolding is a side effect of the A2-73 main function.


First you mean proposed function
Second you don't know what will be the main function
Third check my actual statement rather than MyCroft's misquote